IBRUTINIB PLUS VENETOCLAX WITH MRD-GUIDED DURATION OF TREATMENT IS SUPERIOR TO BOTH CONTINUOUS IBRUTINIB MONOTHERAPY AND FCR FOR PREVIOUSLY UNTREATED CLL: REPORT OF THE PHASE III UK FLAIR STUDY